Skinvisible Pharmaceuticals

Executive Summary

Skinvisible Pharmaceuticals is a US-based biotechnology company specializing in advanced topical and transdermal drug delivery through its patented Invisicare® polymer platform. Founded in 1999, the company operates via strategic licensing partnerships, enabling pharmaceutical partners to leverage Invisicare to enhance drug efficacy and patient compliance for dermatological conditions and systemic diseases such as obesity. Skinvisible's technology offers potential advantages in sustained release, improved bioavailability, and reduced dosing frequency. Although the company is private and lacks a public ticker, its business model reduces direct clinical risk while providing exposure to multiple product candidates through partner pipelines. Key developments include ongoing discussions with potential licensees and expansion of the platform into new therapeutic areas. The executive summary highlights Skinvisible's collaborative approach and technological differentiation, positioning it for growth as partners advance products toward market.

Upcoming Catalysts (preview)

• Q4 2026New Licensing Agreement with a Major Pharma for Obesity or Dermatology Indication40% success
• Q1 2027Expansion of Invisicare Platform into a New Therapeutic Area (e.g., Pain Management)30% success
• TBDProgress Update on Partner-Developed Product Entering Phase 2/3 Trials25% success